MOOD DISORDERS

More documents

Recommendations

Info

138 Mood Disorders [170] Duman RS. Depression: a case of neuronal life and death? Biol Psychiatry 2004;56(3): 140-145. [171] Brand MD, Nicholls DG. Assessing mitochondrial dysfunction in cells. Biochem J 2011;435(2): 297-312. [172] Fagervall I, Ross SB. Inhibition of monoamine oxidase in monoaminergic neurones in the rat brain by irreversible inhibitors. Biochem Pharmacol 1986;35(8): 1381-1387. [173] Smith TE, Weisssbach H, Udenfriend S. Studies on monoamine oxidase: the mecha‐ nism of inhibition of monoamine oxidase by iproniazid. Biochemistry 1963;2(4): 746-751. [174] Haefely W, Burkard WP, Cesura AM, Kettler R, Lorez HP, Martin JR, Richards JG, Scherschlicht R, Da Prada M.: Biochemistry and pharmacology of moclobemide, a prototype RIMA. Psychopharmacology (Berl) 1992;106(Suppl): S6-S14. [175] Lecrubier Y, Guelfi JD. Efficacy of reversible inhibitors of monoamine oxidase-A in various forms of depression. Acta Psychiatr Scand Suppl 1990;360: 18-23. [176] Lecrubier Y. Risk-benefit assessment of newer versus older monoamine oxidase (MAO) inhibitors. Drug Saf 1994;10(4): 292-300. [177] Iwersen S, Schmoldt A. Three suicide attempts with moclobemide. J Toxicol Clin Toxicol 1996;34(2): 223-225. [178] Lotufo-Neto F, Trivedi M, Thase ME. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of de‐ pression. Neuropsychopharmacology 1999;20(3): 226-247. [179] Magder DM, Aleksic I, Kennedy SH. Tolerability and efficacy of high-dose moclobe‐ mide alone and in combination with lithium and trazodone. J Clin Psychopharmacol 2000;20(3): 394-395. [180] Bonnet U. Moclobemide: therapeutic use and clinical studies. CNS Drug Rev 2003;9(1): 97-140. [181] Praško J, Dockery C, Horáček J, Houbová P, Kosová J, Klaschka J, Pašková B, Praško‐ vá H, Seifertová D, Záleský R, Höschl C. Moclobemide and cognitive behavioral ther‐ apy in the treatment of social phobia. A six-month controlled study and 24 months follow up. Neuro Endocrinol Lett 2006;27(4): 473-481. [182] Jauch R, Griesser E, Oesterhelt G, Arnold W, Meister W, Ziegler WH, Guentert TW. Biotransformation of moclobemide in humans. Acta Psychiatr Scand Suppl 1990;360: 87-90. [183] Da Prada M, Kettler R, Keller HH, Burkard WP, Muggli-Maniglio D, Haefely WE. Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J Pharmacol Exp Ther 1989;248(1): 400-414.
Mitochondrial Functions in Mood Disorders http://dx.doi.org/10.5772/53254 [184] Baker GB, Urichuk LJ, McKenna KF, Kennedy SH. Metabolism of monoamine oxi‐ dase inhibitors. Cell Mol Neurobiol 1999;19(3): 411-426. [185] Reyes E, Lisansky J. Effects of tricyclic antidepressants on platelet monoamine oxi‐ dase activity. Clin Pharmacol Ther 1984;35(4): 531-534. [186] Roth JA, Gillis CN. Inhibition of lung, liver and brain monoamine oxidase by imipra‐ mine and desipramine. Biochem Pharmacol 1974;23(6): 1138-1140. [187] Edwards DJ, Burns MO. Effects of tricyclic antidepressants upon human platelet monoamine oxidase. Life Sci 1974;15(12): 2045-2058. [188] Sullivan JL, Dackis C, Stanfield C. In vivo inhibition of platelet MAO activity by tri‐ cyclic antidepressants. Am J Psychiatry 1977;134(2): 188-190. [189] Sullivan JL, Zung WW, Stanfield CN, Cavenar JO Jr. Clinical correlates of tricyclic antidepressant-mediated inhibition of platelet monoamine oxidase. Biol Psychiatry 1978;13(3): 399-407. [190] Davidson J, Mcleod MN, Linnoila M, Kurland AA, White HL. Platelet MAO inhibi‐ tion following tricyclic antidepressant therapy. Am J Psychiatry 1978;135(5): 603-605. [191] Reveley MA, Glover V, Slander M, Coppen A. Absence of platelet monamine oxidase inhibition during amitriptyline or zimelidine treatment. Br J Clin Pharmacol 1979;8(4): 375-378. [192] Green AL, McGachy HA. The inhibition of monoamine oxidase by tricyclic antide‐ pressants: the influence of the nature of the substrate and the source of the enzyme. J Pharm Pharmacol 1987;39(5): 392-394. [193] Green AL, O'Grady JE, Vass M. The effect of some tricyclic antidepressants on the in‐ hibition of mouse brain monoamine oxidase in-vivo by phenelzine. J Pharm Pharma‐ col 1989;41(1): 50-51. [194] Honecker H, Christ W, Müller-Oerlinghausen B, Coper H. Critical evaluation of measurement of platelet monoamine oxidase in man. J Clin Chem Clin Biochem 1976;14(9): 453-458. [195] Nag M. Effect of chlorpromazine, imipramine and lithium on MAO-A and MAO-B activity in rat brain mitochondria. Indian J Exp Biol 2004;42(9): 941-944. [196] Egashira T, Takayama F, Yamanaka Y. Effects of long-term treatment with dicyclic, tricyclic, tetracyclic, and noncyclic antidepressant drugs on monoamine oxidase ac‐ tivity in mouse brain. Gen Pharmacol 1996;27(5): 773-778. [197] Egashira T, Takayama F, Yamanaka Y. The inhibition of monoamine oxidase activity by various antidepressants: differences found in various mammalian species. Jpn J Pharmacol 1999;81(1): 115-121. 139
Page 1 and 2:
MOOD DISORDERS Edited by Neşe Koca
Page 3:
free online editions of InTech Book
Page 6 and 7:
VI Contents Chapter 8 Mood Disorder
Page 9 and 10:
Chapter 1 Murine Models for Develop
Page 11 and 12:
Murine Models for Developping an In
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Chapter 2 Depression and Glucose Me
Page 33 and 34:
2.2. Clinical symptoms Depression i
Page 35 and 36:
al., 2011, in a group of more than
Page 37 and 38:
Depression and Glucose Metabolism (
Page 39 and 40:
psychosocial factors which associat
Page 41 and 42:
Page 43 and 44:
≤ 0.01 for all parameters). Reduc
Page 45 and 46:
Scale Groups SSRI´s/SNRI´s N Mean
Page 47 and 48:
studies and almost disappears in mo
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Depression: Classification, Culture
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Regier (2004, p. 25) describes the
Page 63 and 64:
sation takes hold and a degree of c
Page 65 and 66:
clear that lesser forms of unhappin
Page 67:
[20] MedlinePlus (2012) http://www.
Page 70 and 71:
62 Mood Disorders Although there is
Page 72 and 73:
64 Mood Disorders Emotional symptom
Page 74 and 75:
66 Mood Disorders These symptoms ca
Page 76 and 77:
68 Mood Disorders creasingly delega
Page 78 and 79:
70 Mood Disorders chapter; therefor
Page 80 and 81:
72 Mood Disorders 7.2.1. Reinforcem
Page 82 and 83:
74 Mood Disorders fect on the patie
Page 84 and 85:
76 Mood Disorders Some patients may
Page 86 and 87:
78 Mood Disorders will get up at 8
Page 88 and 89:
80 Mood Disorders peutic setting un
Page 90 and 91:
82 Mood Disorders detailed in this
Page 92 and 93:
84 Mood Disorders 8.3. Cognitive te
Page 94 and 95:
86 Mood Disorders and correctly und
Page 96 and 97: 88 Mood Disorders Therapist: “Ima
Page 98 and 99: 90 Mood Disorders 1. Analysis of be
Page 100 and 101: 92 Mood Disorders [7] Wittchen, H.-
Page 102 and 103: 94 Mood Disorders [36] Hollon, S.D.
Page 104 and 105: 96 Mood Disorders [68] Yorbik, O.,
Page 106 and 107: 98 Mood Disorders [103] Lindsley, D
Page 109 and 110: Mitochondrial Functions in Mood Dis
Page 111 and 112: Genetic defects or stress can cause
Page 113 and 114: Figure 2. Representation of process
Page 115 and 116: ain. Normally the H 2O 2 is then in
Page 117 and 118: ADP level State 1 Low State 2 High
Page 119 and 120: 2.3.2. Uncoupling proteins Uncoupli
Page 121 and 122: Complex IV inhibitors KCN and sodiu
Page 123 and 124: pathogenesis of axonal degeneration
Page 125 and 126: 3.3. Inflammatory and neurodegenera
Page 127 and 128: plete data exist on the effect of p
Page 129 and 130: 4.3. Effects of mood stabilizers on
Page 131 and 132: Antidepressant Biological model Aff
Page 133 and 134: Mood stabilizer Biological model Af
Page 145: Mitochondrial Functions in Mood Dis
Page 153 and 154: Long-Term Adaptive Changes Induced
Page 157 and 158: 5-HT 1B/1D (-) SERT 5-HT 1A (-) [5-
Page 161 and 162: postsynaptic 5-HT 1A receptors in t
Page 165 and 166: 3.3. Neurotrophins modulation by 5-
Page 167 and 168: BDNF levels before treatment, and a
Page 169 and 170: References Long-Term Adaptive Chang
Page 189 and 190: Biological Markers and Genetic Fact
Page 191 and 192: Collectively, serotonin receptor, T
Page 193 and 194: Biological Markers and Genetic Fact
Page 195 and 196: imaging and genetics have been emer
Page 197 and 198:
Biological Markers and Genetic Fact
Page 199 and 200:
Page 201 and 202:
Page 203:
Page 206 and 207:
198 Mood Disorders pressed. Already
Page 208 and 209:
200 Mood Disorders cy may takes its
Page 210 and 211:
202 Mood Disorders of the developin
Page 212 and 213:
204 Mood Disorders 2.2.1. Touch and
Page 214 and 215:
206 Mood Disorders found by Jung et
Page 216 and 217:
208 Mood Disorders mize the risk of
Page 218 and 219:
210 Mood Disorders [20] Misri S, Ko
Page 220 and 221:
212 Mood Disorders [49] Melley M, C
Page 222 and 223:
214 Mood Disorders [78] Rahman A, I
Page 224 and 225:
216 Mood Disorders [106] Taylor A,
Page 226 and 227:
218 Mood Disorders [134] Esquivel-S
Page 229 and 230:
Cognitive Functions in Euthymic Bip
Page 231 and 232:
Page 233 and 234:
Page 235 and 236:
4. Discussion 4.1. Cognitive functi
Page 237 and 238:
poor functional outcome. Executive
Page 239 and 240:
Page 241 and 242:
References Cognitive Functions in E
Page 243 and 244:
Page 245 and 246:
Page 247:
Page 250 and 251:
242 Mood Disorders Figure 1. 2. Fat
Page 252 and 253:
244 Mood Disorders 3.1. The role of
Page 254 and 255:
246 Mood Disorders dylserine is syn
Page 256 and 257:
248 Mood Disorders and 42 (Aβ 42)
Page 258 and 259:
250 Mood Disorders about omega-3 fa
Page 260 and 261:
252 Mood Disorders First, DHA compe
Page 262 and 263:
254 Mood Disorders tained from the
Page 264 and 265:
256 Mood Disorders [11] Salem, N.,
Page 266 and 267:
258 Mood Disorders bind to retinoid
Page 268 and 269:
260 Mood Disorders [67] Yao, J. K.,
Page 271 and 272:
Chapter 11 Neuronal Insulin Recepto
Page 273 and 274:
Neuronal Insulin Receptor Signaling
Page 275 and 276:
Page 277 and 278:
Page 279 and 280:
Page 281 and 282:
Page 283 and 284:
Page 285 and 286:
involved in the various cognitive a
Page 287 and 288:
Page 289 and 290:
Page 291 and 292:
Page 293 and 294:
Page 295:
show all

MOOD DISORDERS

Create successful ePaper yourself

Delete template?

Save as template?